Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

574 ARTÍCULOS , VIENDO DEL 511 AL 525

Hospital incidence, mortality and costs of Alzheimer's disease in Spain: a retrospective multicenter study

Darbà J, Marsà A.

Expert Rev Pharmacoecon Outcomes Res. 2021 Oct;21(5):1101-1106. doi: 10.1080/14737167.2020.1820328. Epub 2020 Sep 14.

[Position paper of the Austrian Alzheimer Association (Österreichische Alzheimer Gesellschaft, ÖAG) : Effects of the COVID-19 pandemic in Austria on people with dementia and their care environment-problem areas, recommendations, and strategies]

Defrancesco M, Bancher C, Dal-Bianco P, Hinterhuber H, Schmidt R, Struhal W, Ransmayr G, Stögmann E, Marksteiner J.

Neuropsychiatr. 2021 Mar;35(1):35-47. doi: 10.1007/s40211-020-00363-9. Epub 2020 Oct 29.

Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery

Hampel H, Vergallo A, Caraci F, Cuello AC, Lemercier P, Vellas B, Giudici KV, Baldacci F, Hänisch B, Haberkamp M, Broich K, Nisticò R, Emanuele E, Llavero F, Zugaza JL, Lucía A, Giacobini E, Lista S; Alzheimer Precision Medicine Initiative.

Neuropharmacology. 2021 Mar 1;185:108081. doi: 10.1016/j.neuropharm.2020.108081. Epub 2020 May 11.

Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate

van Dyck CH, Arnsten AFT, Padala PR, Brawman-Mintzer O, Lerner AJ, Porsteinsson AP, Scherer RW, Levey AI, Herrmann N, Jamil N, Mintzer JE, Lanctôt KL, Rosenberg PB.

Am J Geriatr Psychiatry. 2021 Jan;29(1):51-62. doi: 10.1016/j.jagp.2020.04.026. Epub 2020 May 5.

Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients

Vidoni ED, Choi IY, Lee P, Reed G, Zhang N, Pleen J, Mahnken JD, Clutton J, Becker A, Sherry E, Bothwell R, Anderson H, Harris RA, Brooks W, Wilkins HM, Mosconi L, Burns JM, Swerdlow RH.

Alzheimers Dement. 2021 Jan;17(1):7-17. doi: 10.1002/alz.12156. Epub 2020 Jul 27.

Pattern of treatment of behavioural and psychological symptoms of dementia and pain: evidence on pharmacoutilization from a large real-world sample and from a centre for cognitive disturbances and dementia

Scuteri D, Vulnera M, Piro B, Bossio RB, Morrone LA, Sandrini G, Tamburin S, Tonin P, Bagetta G, Corasaniti MT.

Eur J Clin Pharmacol. 2021 Feb;77(2):241-249. doi: 10.1007/s00228-020-02995-w. Epub 2020 Sep 15.

Linking the Mini-Mental State Examination, the Alzheimer's Disease Assessment Scale-Cognitive Subscale and the Severe Impairment Battery: evidence from individual participant data from five randomised clinical trials of donepezil

Levine SZ, Yoshida K, Goldberg Y, Samara M, Cipriani A, Efthimiou O, Iwatsubo T, Leucht S, Furukawa TA.

Evid Based Ment Health. 2021 May;24(2):56-61. doi: 10.1136/ebmental-2020-300184. Epub 2020 Oct 6.

Psychotropic Medication and Cognitive, Functional, and Neuropsychiatric Outcomes in Alzheimer's Disease (AD)

Oh ES, Rosenberg PB, Rattinger GB, Stuart EA, Lyketsos CG, Leoutsakos JS.

J Am Geriatr Soc. 2021 Apr;69(4):955-963. doi: 10.1111/jgs.16970. Epub 2020 Dec 31.

Novel therapeutic strategies for Alzheimer's disease targeting brain cholesterol homeostasis

Samant NP, Gupta GL.

Eur J Neurosci. 2021 Jan;53(2):673-686. doi: 10.1111/ejn.14949. Epub 2020 Sep 18.

36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease

Soininen H, Solomon A, Visser PJ, Hendrix SB, Blennow K, Kivipelto M, Hartmann T; LipiDiDiet clinical study group.

Alzheimers Dement. 2021 Jan;17(1):29-40. doi: 10.1002/alz.12172. Epub 2020 Sep 13.

Preliminary Evidence That Cortical Amyloid Burden Predicts Poor Response to Antidepressant Medication Treatment in Cognitively Intact Individuals With Late-Life Depression

Taylor WD, Boyd BD, Elson D, Andrews P, Albert K, Vega J, Newhouse PA, Woodward ND, Kang H, Shokouhi S.

Am J Geriatr Psychiatry. 2021 May;29(5):448-457. doi: 10.1016/j.jagp.2020.09.019. Epub 2020 Sep 28.

Therapeutic implications of hypothalamic-pituitaryadrenal-axis modulation in Alzheimer's disease: A narrative review of pharmacological and lifestyle interventions

Watermeyer T, Robb C, Gregory S, Udeh-Momoh C.

Front Neuroendocrinol. 2021 Jan;60:100877. doi: 10.1016/j.yfrne.2020.100877. Epub 2020 Oct 9.

Cognitive effects and acceptability of non-invasive brain stimulation on Alzheimer's disease and mild cognitive impairment: a component network meta-analysis

Chu CS, Li CT, Brunoni AR, Yang FC, Tseng PT, Tu YK, Stubbs B, Carvalho AF, Thompson T, Rajji TK, Yeh TC, Tsai CK, Chen TY, Li DJ, Hsu CW, Wu YC, Yu CL, Liang CS.

J Neurol Neurosurg Psychiatry. 2021 Feb;92(2):195-203. doi: 10.1136/jnnp-2020-323870. Epub 2020 Oct 28.

β-amyloid: The known unknowns

Ayton S, Bush AI.

Ageing Res Rev. 2021 Jan;65:101212. doi: 10.1016/j.arr.2020.101212. Epub 2020 Nov 11.

Association between chronic stress and Alzheimer's disease: Therapeutic effects of Saffron

Saeedi M, Rashidy-Pour A.

Biomed Pharmacother. 2021 Jan;133:110995. doi: 10.1016/j.biopha.2020.110995. Epub 2020 Nov 21.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias